480 related articles for article (PubMed ID: 24135559)
1. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
2. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
Kim S; Eleff M; Nicolaou N
Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
[TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Gaffney DC; Soyer HP; Simpson F
Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
[TBL] [Abstract][Full Text] [Related]
8. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.
Falivene S; Giugliano FM; Grimaldi AM; Di Franco R; Toledo D; Muto M; Cammarota F; Borzillo V; Ascierto PA; Muto P
BMC Dermatol; 2014 Sep; 14():15. PubMed ID: 25270710
[TBL] [Abstract][Full Text] [Related]
9. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
10. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
12. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.
de Andrade DA; Machiels JP
Curr Opin Oncol; 2012 May; 24(3):211-7. PubMed ID: 22498572
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
[TBL] [Abstract][Full Text] [Related]
15. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
